

(51) International Patent Classification:
Not classified(21) International Application Number:
PCT/SG2022/050473(22) International Filing Date:
07 July 2022 (07.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202108149Q 26 July 2021 (26.07.2021) SG
10202112107V 29 October 2021 (29.10.2021) SG

(71) Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; 10 Hospital Boulevard, #19-01, Outram Community Hospital, Singapore 168582 (SG).


(72) Inventors: SU, Xinyi; c/o Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673

(SG). ZHAO, Xinxin; c/o Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 (SG). TAN, Shu Woon, Queenie; c/o Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 (SG). HUNZIKER, Walter; c/o Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 (SG). LIU, Zengping; c/o Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 (SG). LOH, Xian Jun; c/o Institute of Materials Research and Engineering, 2 Fusionopolis Way, Innovis, Singapore 138634 (SG). XUE, Kun; c/o Institute of Materials Research and Engineering, 2 Fusionopolis Way, Innovis, Singapore 138634 (SG). BARATHI, Veluchamy Amutha; The Academia, 20 College Road, Level 6, Singapore 169856 (SG).

(74) Agent: DONALDSON & BURKINSHAW LLP; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: AN ANTI-ANGIOGENIC AGENT AND RELATED METHODS



(57) Abstract: There is provided an anti-angiogenic agent comprising: a multi-block copolymer in the form of one or more micelles, wherein the copolymer comprises a first poly (alkylene glycol) block, a second poly (alkylene glycol) block and a polyester block. There is also provided a method of preparing said anti-angiogenic agent and medical uses of said anti-angiogenic agent.

[Continued on next page]

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*